Enumeral Biomedical Holdings, Inc. (OTCBB:CEUL) Files An 8-K Unregistered Sales of Equity Securities
Item 3.02. Unregistered Sale of Equity Securities.
The information contained in Item 1.01 of this Current Report on
Form 8-K is incorporated herein by reference.
Item 3.03. Material Modification to Rights of Security
Holders.
The information contained in Item 1.01 of this Current Report on
Form 8-K is incorporated herein by reference.
Item 7.01. Regulation FD Disclosure.
On December 12, 2016, the Company issued a press release with
respect to the Offer to Amend and Exercise. The press release is
attached to this Current Report on Form 8-K as Exhibit 99.1 and
is incorporated herein by reference.
The information contained in this Item 7.01 of this Current
Report on Form 8-K, including the information contained in
Exhibit 99.1, is being furnished and shall not be deemed filed
for purposes of Section18 of the Securities and Exchange Act of
1934, as amended, or incorporated by reference into any filing of
the Company, whether made before or after the date hereof,
regardless of any general incorporation language in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
| 10.1 |
Form of Registration Rights Agreement (Incorporated by reference to Exhibit (d)(2) of the tender offer statement on Schedule TO, as filed with the Securities and Exchange Commission on October 28, 2016 (005-88781)). |
| 10.2* |
Amendment to Amended and Restated Warrants to Purchase Stock, dated as of December 12, 2016, between Enumeral Biomedical Holdings, Inc. and PacWest Bancorp. |
| 99.1** | Press Release, dated December 12, 2016. |
* Filed herewith
** Furnished herewith
About Enumeral Biomedical Holdings, Inc. (OTCBB:CEUL)
Enumeral Biomedical Holdings, Inc. is a biopharmaceutical company focused on discovering and developing antibody immunotherapies that help the immune system fight cancer and other diseases. The Company utilizes a platform technology that facilitates the resolution measurement of immune cell function within small tissue biopsy samples. Its initial focus is on the development of a pipeline of monoclonal antibody drugs targeting established and immuno-modulatory receptors. Its platform technology is a microwell array technology that detects secreted molecules (such as antibodies and cytokines) and cell surface markers at the level of single, live cells and enables recovery of single, live cells of interest. Its program involves antibodies against the Programmed Cell Death receptor, commonly known as (PD-1). In addition to its PD-1 antibody program, it is developing antibody drug candidates for a number of immunomodulatory protein targets, including TIM-3, LAG-3, OX40, TIGIT and VISTA. Enumeral Biomedical Holdings, Inc. (OTCBB:CEUL) Recent Trading Information
Enumeral Biomedical Holdings, Inc. (OTCBB:CEUL) closed its last trading session at 0.150 with shares trading hands.
